

iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
Sep 22, 2023
Experts Naval Daver, MD and Gail Roboz, MD discuss new treatments in AML, focusing on FLT3 inhibitors, novel combinations, and treating relapsed disease. They also explore treatment options, managing patient expectations, and the benefits of HMA in salvage treatment. Additionally, the importance of guilt and Venetoclax for rapid and deep responses in AML patients eligible for transplant is emphasized.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 2min
Response to Guilt or Anib in Relapsed Flip Three Mutated AML
01:32 • 2min
Treatment Options for Acute Myeloid Leukemia (AML)
03:53 • 4min
Treatment Approach for Acute Myeloid Leukemia (AML) Patients Eligible for Stem Cell Transplant
07:56 • 15min
Mutations in ELN 2022, CPX351, and Challenges in HM-A-Venn
23:06 • 2min
Therapeutic strategies and options for acute myeloid leukemia (AML)
24:53 • 3min